Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs ...
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the ...
Indianapolis-based Eli Lilly's expansion into Bristol will focus on manufacturing injectable medications, device assembly and ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...